Company: DARE
Filing Date: 2025-06-25
Form Type: 8-K
Source: 0001641172-25-016374
Chunk: 0

Company: Dare Bioscience, Inc.
Filing Date: 2025-06-25
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events.

On
June 24, 2025, Daré Bioscience, Inc. (“ Daré,” the “ Company,” “we,” “us” or
“our”), received a letter from The Nasdaq Stock Market LLC (“ Nasdaq”) informing us that the Nasdaq Hearings Panel
(the “ Panel”) has amended its decision in the delisting appeal we previously submitted and approved our further modified
multi-step plan (our “ Plan”) to demonstrate compliance with either Nasdaq Listing Rule 5550(b)(1) or 5550(b)(2). The Panel’s
amended decision and approval of our Plan does not change the end date of the conditional continued listing period previously granted
by the Panel, which is August 12, 2025.

As
previously reported, we have not been in compliance with Nasdaq Listing Rule 5550(b) since August 2024. Nasdaq Listing Rule 5550(b)(1)
requires a company to maintain stockholders’ equity of at least $2.5 million, which we refer to as the “ Stockholders’
Equity Rule,” and Nasdaq Listing Rule 5550(b)(2) requires a company to maintain a minimum market value of listed securities of
$35.0 million, which we refer to as the “ Minimum MVLS Rule.” A company will satisfy the continued listing requirement under
Nasdaq Listing Rule 5550(b) if it meets either the Stockholders’ Equity Rule or the Minimum MVLS Rule.

Our
Plan includes demonstrating compliance with either the Stockholders’ Equity Rule or the Minimum MVLS Rule on or before July 31,
2025, and, if we demonstrate compliance with the Minimum MVLS Rule, publicly disclosing transactions we undertook to increase our stockholders’
equity and an indication of our stockholders’ equity following such transactions, as well as providing the Panel with updates and
information on our fundraising plans and updated income projections for the next 12 months. No assurances can be given that we will be
successful in executing against our Plan or that we will satisfy either the Stockholders’ Equity Rule or the Minimum MVLS Rule
by July 31 or August 12, 2025. If we fail to execute on our Plan to the Panel’s satisfaction and remain non-compliant with the
Stockholders’ Equity Rule and the Minimum MVLS Rule, the Panel may issue a decision to delist our common stock and suspend trading
in